Is LANXESS (XTRA:LXS) A Bargain On Analyst Downgrades And Envalior Doubts?
Recent downgrades from BNP Paribas and Berenberg have pushed LANXESS (XTRA:LXS) back into focus, as analysts question how reliably earnings can stabilize and how much value the Envalior partnership can realistically deliver.
LANXESS has seen its share price under pressure for much of the year, with the latest close at €12.47 and the 90 day share price return down 19.24% as investors reassess earnings risks and the Envalior contribution following the recent downgrades.
Scan how other potentially undervalued companies with healthier sentiment compare to LANXESS by reviewing our curated list of 188 high quality undervalued stocks in the market right now.
LANXESS runs a broad specialty chemicals operation, yet the share price fall and fresh downgrades raise a sharper question: Is this a solid platform temporarily mispriced, or is the current valuation simply reflecting the risks more accurately?
Most Popular Narrative: 19% Undervalued
The most followed narrative for LANXESS puts fair value at €15.41 using a 9.31% discount rate, compared with the latest close at €12.47. This frames the recent downgrades against a model that still sees room between price and estimated worth.
Secular increases in regulation and consumer demand for sustainable materials are accelerating the shift toward green chemicals. LANXESS's ongoing investments in eco-friendly product lines and the closure of high CO2 assets directly target this opportunity, which may help expand its addressable market and support revenue and pricing.
See why 9 investors see LANXESS as 19% undervalued.
Result: Fair Value of €15.41 (UNDERVALUED)
Still, rising competition from Chinese producers and structurally high European energy costs could pressure LANXESS and challenge the optimistic recovery narrative that investors are weighing.
Find out about the key risks to this LANXESS narrative.
Next Steps
Mixed signals like these rarely stay unresolved for long. Review the data yourself and stress test your own thesis using the 2 key rewards and 1 important warning sign.
Looking for more LANXESS investment ideas?
If LANXESS has you rethinking your portfolio, use this moment to line up fresh opportunities before the next round of earnings resets expectations again.
- Target stronger upside potential by scanning companies that screen as attractively priced on quality and valuation using the 188 high quality undervalued stocks.
- Strengthen your income stream by reviewing a focused set of higher yielding payers through the 216 dividend fortresses.
- Lower the overall risk of your portfolio by filtering for sturdier balance sheets and fundamentals with the list of solid balance sheet and fundamentals (203 results).
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com